#EULAR2026 LB0002 More great news for dual IL17A and -F blockade. An open label Phase II study of Sonelokimab, a novel IL-17A- and IL-17F-inhibiting Nanobody'-3 in #axSpA: clinical efficacy, improvement in PROM and imaging inflammation. Looking forward to the RCT phase @RheumNow https://t.co/Xtxa8fALzN

• https://x.com/Yuz6Yusof/status/2063222743462481996/photo/1
• https://x.com/Yuz6Yusof/status/2063222743462481996/photo/1

Interesting data on the effect of AB-101 + RTX on refractory RA, SSc and SjD. Curious about long term results and potential position in tx strategies LB0006 @RheumNow #EULAR2026 https://t.co/opbh8yGmwO

• https://x.com/RHEUMarampa/status/2063224197355085825/photo/1
• https://x.com/RHEUMarampa/status/2063224197355085825/photo/1
• https://x.com/RHEUMarampa/status/2063224197355085825/photo/1
• https://x.com/RHEUMarampa/status/2063224197355085825/photo/1

Abstr LB0004 CC312 is a CD19/CD3/CD28 tri-specific T cell engager and sustains SRI-4 responses beyond one year with rapid, deep B-cell depletion in autoimmune diseases. Not CAR-T. Not a conventional biologic. A T cell engager that redirects your own immune cells to deplete B https://t.co/rTs3Rg7BPe

• https://x.com/synovialjoints/status/2063224606043885962/photo/1

CAR-T without the CAR-T risks? AB-101, an off-the-shelf NK cell therapy + RTX, delivered in refractory RA, Sjögren, and SSc (n=31): RA ACR50 71%, SSc mRSS -9.5, SjD ClinESS DAI -8.6 at 6 mo. Outpatient delivery without CAR-T associated AEs? @RheumNow #EULAR2026 LB0003 https://t.co/xi6ZdLwHcN

• https://x.com/JihaRheum/status/2063224633923658191/photo/1

#SLE Rx options Determining #MOA #TYK2 #sig w #deucravacitinib #IFN sig in active #SLE ⬇️ in #anifrolumab #upa #deucra #repeat renal #bx in #obinutuzimab ➡️ Clears B cells #Dapriluzimab & other MOAs ⬇️AntiDNA ⬆️complements #EULARbest @RheumNow #EULAR2026 #POS1364, OP0160,336

All content is independently chosen and produced by the RheumNow faculty. Our expanded #EULAR2026 coverage is made possible by support from Bristol Myers Squibb and UCB.

#EULAR2026 LB0003 CAR-T is not scalable. In a Phase 2a of off-the-shelf AB-101 allogenic NK + low dose conditioning (Cyclo & Flud) + Rituximab: preliminary efficacy & safety profile in severe-refractory RA (N=15), SjD (11), SSc (5). Longer FU & Comparator is needed @RheumNow https://t.co/gQniufREQC

• https://x.com/Yuz6Yusof/status/2063227779928166838/photo/1
• https://x.com/Yuz6Yusof/status/2063227779928166838/photo/1

#EULAR2026 LB0004 First BiTE, now TriTE! Tri-specific CC312 CD19/CD3/CD28 (i.e. CD28 co-stimulates Tcell activation) showed deep Bcell depletion, early efficacy & safety in 10 #SLE patients up to 52WKs. Promising but longer FU needed to see if repeat dosing needed @RheumNow https://t.co/6Lbm9LYJrY

• https://x.com/Yuz6Yusof/status/2063230586743927190/photo/1
• https://x.com/Yuz6Yusof/status/2063230586743927190/photo/1

JASMINE-SLE: Proof of concept study on Nipocalimab for SLE SRI-4 met at wk 24 for the 15 mg/kg q2w dose va. PBO Improvement of SRI-4 composite & LLDAS at wk 52 LB0007 @RheumNow #EULAR2026 https://t.co/0wzHyid3dy

• https://x.com/RHEUMarampa/status/2063234107761414619/photo/1
• https://x.com/RHEUMarampa/status/2063234107761414619/photo/1

#EULAR2026 LB0005 More promising news in #PMR. Phase 3 RCT of Baricitinib + GC Taper in N=46: Part 1: BARI vs PBO 65% vs 17% GC-Free Remission at WK16 2: PBO-BARI improved response 17% to 65% at WK28 3: Lower remission rate in those stopped BARI vs continued at WK44 @RheumNow https://t.co/D77aHcACJE

• https://x.com/Yuz6Yusof/status/2063238362324979886/photo/1
• https://x.com/Yuz6Yusof/status/2063238362324979886/photo/1

Baricitinib did not demonstrate non-inferiority w/ TNFi for first VTE in the RA-BRIDGE and RA-BRANCH trials. Identifying high-risk pts and individualizing tx is paramount. LB0009 @RheumNow #EULAR2026 https://t.co/MSiBq0FnEq

• https://x.com/RHEUMarampa/status/2063240813627257030/photo/1
• https://x.com/RHEUMarampa/status/2063240813627257030/photo/1

Abstr LB0009 Baricitinib vs TNFi in RA patients enriched for VTE risk. 3,640 patients. 3.7 years median follow-up. VTE: HR 1.61 (95% CI 0.97–2.66) non-inferiority not demonstrated MACE: HR 1.06 no cardiovascular excess Serious infections: HR 1.32 (p<0.05) @RheumNow https://t.co/NSNRJi9B4r

• https://x.com/synovialjoints/status/2063240912851857742/photo/1

Abstr LB0009 Baricitinib vs TNFi in VTE-enriched RA. 3,640 patients. 3.7 years. Safety endpoints VTE HR 1.61 non inferiority not met Serious infections HR 1.32 (p<0.05) MACE HR 1.06 reassuring @RheumNow #EULAR2026 https://t.co/nR6TMowlYS

• https://x.com/synovialjoints/status/2063242046660358473/photo/1

#EULAR2026 Updated recommendations on the management of PMR &LVV. A pleasure to have been part of this huge piece of work, covering 3 distinct conditions, and both diagnosis & management principles. Watch this space for full guideline coming soon! #EULAR2026 @RheumNow https://t.co/CUvaQVSU8k

• https://x.com/DrMiniDey/status/2063244890520141836/photo/1
• https://x.com/DrMiniDey/status/2063244890520141836/photo/1

#EULAR2026 LB0006 Beyond conventional immunosuppressant, a multicentre RCT (N=145) in China showed mTOR-i Sirolimus + SOC met primary endpoint (SRI-4) vs PBO + SOC in #SLE. Favourable safety. Frequent AE: high cholesterol & low WCC. Unclear position in treatment pathway @RheumNow https://t.co/OiFp06467v

• https://x.com/Yuz6Yusof/status/2063245455014633559/photo/1